Risdiplam - Another ray of hope for SMA patients
Spinal muscular atrophy is an autosomal recessive
degenerative disease of motor neurons. Caused by homozygous deletion of
survival motor neuron 1 (SMN1) gene on chromosome 5q,
characterized by the progressive denervation of muscles leading
progressive loss of motor function. SMA is divided into different
subtypes based on age of onset and maximum function achieved.
At present the focus of research is on strategies to
increase the body’s production of the SMN protein. In 2019, FDA approved
first gene replacement therapy to be used in SMA (Zolgensma), which acts
by replacing the mutated non-working SMN gene with a working copy
of the gene. The cost of one time intravenous dose for treatment of
patients with SMA costs approximately 16 crore rupees.
A team of researchers studied the safety and efficacy
of Risdiplam, which is an orally administered molecule that increases
the level of functional SMN protein by modifying SMN2 pre–messenger
RNA splicing. Use of risdiplam resulted in higher percentages of SMA
affected infants showing improve-ment of motor functions and attainment
of motor milestones compared to the control group, after 12 months of
therapy.
Hopefully this will act as a game changer for infants
affected with SMA and their families, as this will bring down the cost
of treatment and increase the accessibility.
(New England Journal of Medicine 29 July, 2021)
Vaccination strategy for the COVID-19 exposed
Since the detection of the first case in China in
December, 2019, COVID-19 has spread around the world and infected
approximately 200 million people and caused 4.2 million deaths globally.
Apart from all this, it had affected the lives of much more people by
affecting their livelihood and access to the adequate nutrition. Now,
with development of vaccine against the COVID-19, a hope has started to
rise that situation will improve. But the cost of vaccine and the
availability are the two factors affecting the coverage.
A team from Rush University, Chicago studied the
levels of SARS-CoV-2 spike immunoglobin (Ig) G antibody levels after 1
and 2 BNT162b2 doses in previously infected individuals compared with
those without previous infection. Their observations showed that higher
levels SARS-CoV-2 spike IgG antibody levels in previously infected
individuals after 1 dose of BNT162b2 vaccine compared with
infection-naive individuals after two doses. In previously infected
individuals, after the second dose, the rise in SARS-CoV-2 spike IgG
levels was not significant compared with the first dose, suggesting that
one dose may be acceptable in this group. But they also cautioned that a
positive PCR diagnosis alone was not sufficient to take off the
requirement of second dose of the vaccine.
These findings might redefine the current vaccination
strategy, especially for previously infected individuals, and could free
up of millions of additional doses thus decreasing the burden on the
economies and increase the availability for larger masses.
(JAMA Network Open 6 August, 2021)
Spectral power of EEG: Classify HIE in real time
Birth asphyxia is a major cause of neonatal mortality
worldwide, contributing to upto 24% of all neonatal deaths and 11% of
under-5 deaths globally. A significant proportion of these babies
survive with life-long morbidities. Picking up the moderate and severe
forms of the hypoxic ischemic encephalopathy (HIE) is relatively easier
compared to the milder form due to lack of definition and evolution of
the clinical signs over a period.
Researchers from the Dallas, Texas studied the
electroencephalographic (EEG) power as an objective biomarker of the
evolution of clinical signs of encephalopathy in newborns with various
forms of HIE. Their findings revealed that the delta power and total
power are sensitive real time markers for tracking the evolution of HIE
from one form to another and can help in picking up the mild forms also.
This can help in monitoring and timely beginning of the interventions in
order to improve the overall outcome of such babies.
(Pediatric Neurology 12 June, 2021)
Adolescent mental wellbeing: Time to act
Mental health is one of the important aspects of
health, which is started getting attention over last few decades. But
with the easy availability of internet and round the clock access to it,
more and more youngsters are getting addicted to the screens and
spending most of their time indoors with limited physical activity. This
is not only affecting their physical health but also causing a decline
in their mental wellbeing.
Recently, in an international multi-centric
observational study, involving 577 475 adolescents, researchers studied
the gender-stratified relationships between screen time, mental
wellbeing and physical activity. Results showed that increased screen
time, exceeding 1 hour per day is detrimental for the mental wellbeing
of adolescents, on the contrary, increased physical activity levels are
beneficial for the mental wellbeing.Duration of the screen time and
physical activity are the two main factors which have a dose dependent
association with life satisfaction and mental wellbeing in the
adolescents.
Thus, it is high time to plan and implement some
public health strategies in order to save our younger generations from
the ill effects of the technology.
(Lancet Child and Adolescent Health 09 August, 2021)